

# CYMEVENE<sup>®</sup>



## GANCICLOVIR

---

Vials 500 mg,

### NAME OF THE MEDICINAL PRODUCT

Cymevene<sup>®</sup> 500 mg vials

### WARNING

**THE CLINICAL TOXICITY OF CYMEVENE-IV INCLUDES GRANULOCYTOPENIA, ANEMIA AND THROMBOCYTOPENIA. IN ANIMAL STUDIES GANCICLOVIR WAS CARCINOGENIC, TERATOGENIC AND CAUSED ASPERMATOGENESIS.**

**CYMEVENE-IV IS INDICATED FOR USE ONLY IN THE TREATMENT OF CYTOMEGALOVIRUS (CMV) RETINITIS IN IMMUNOCOMPROMISED PATIENTS AND FOR THE PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE (see INDICATIONS AND USAGE).**

### DESCRIPTION

Ganciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV). CYMEVENE-IV is the brand name for ganciclovir sodium for injection.


CYMEVENE-IV is available as sterile lyophilized powder in strength of 500 mg per vial for intravenous administration only. Each vial of CYMEVENE-IV contains the equivalent of 500 mg ganciclovir as the sodium salt (46 mg sodium). Reconstitution with 10 mL of Sterile Water for Injection, USP, yields a solution with pH 11 and a ganciclovir concentration of approximately 50 mg/mL. Further dilution in an appropriate intravenous solution must be performed before infusion (see **DOSAGE AND ADMINISTRATION**).

Ganciclovir is a white to off-white crystalline powder with a molecular formula of  $C_9H_{13}N_5O_4$  and a molecular weight of 255.23. The chemical name for ganciclovir is 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl]guanine. Ganciclovir is a polar hydrophilic compound with a solubility of 2.6 mg/mL in water at 25°C and an n-octanol/water partition coefficient of 0.022. The pK<sub>a</sub>s for ganciclovir are 2.2 and 9.4.


Ganciclovir, when formulated as monosodium salt in the IV dosage form, is a white to off-white lyophilized powder with the molecular formula of  $C_9H_{12}N_5NaO_4$ , and a molecular

weight of 277.22. The chemical name for ganciclovir sodium is 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy[methyl]guanine, monosodium salt. The lyophilized powder has an aqueous solubility of greater than 50 mg/mL at 25°C. At physiological pH, ganciclovir sodium exists as the un-ionized form with a solubility of approximately 6 mg/mL at 37°C.

The chemical structures of ganciclovir sodium and ganciclovir are:



ganciclovir sodium



ganciclovir

All doses in this insert are specified in terms of ganciclovir.

## **VIROLOGY**

### **Mechanism of Action**

Ganciclovir is an acyclic nucleoside analogue of 2'-deoxyguanosine that inhibits replication of herpes viruses. Ganciclovir has been shown to be active against cytomegalovirus (CMV) and herpes simplex virus (HSV) in human clinical studies.

To achieve anti-CMV activity, ganciclovir is phosphorylated first to the monophosphate form by a CMV-encoded (UL97 gene) protein kinase homologue, then to the di- and triphosphate forms by cellular kinases. Ganciclovir triphosphate concentrations may be 100-fold greater in CMV-infected than in uninfected cells, indicating preferential phosphorylation in infected cells. Ganciclovir triphosphate, once formed, persists for days in the CMV-infected cell. Ganciclovir triphosphate is believed to inhibit viral DNA synthesis by (1) competitive inhibition of viral DNA polymerases; and (2) incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.

### **Antiviral Activity**

The median concentration of ganciclovir that inhibits CMV replication ( $IC_{50}$ ) in vitro (laboratory strains or clinical isolates) has ranged from 0.02 to 3.48  $\mu\text{g/mL}$ . Ganciclovir inhibits mammalian cell proliferation ( $CIC_{50}$ ) in vitro at higher concentrations ranging from 30 to 725  $\mu\text{g/mL}$ . Bone marrow-derived colony-forming cells are more sensitive ( $CIC_{50}$  0.028 to 0.7  $\mu\text{g/mL}$ ). The relationship of in vitro sensitivity of CMV to ganciclovir and clinical response has not been established.

### **Clinical Antiviral Effect of CYMEVENE-IV and Ganciclovir Capsules**

#### **CYMEVENE-IV**

In a study of CYMEVENE-IV treatment of life- or sight-threatening CMV disease in immunocompromised patients, 121 of 314 patients had CMV cultured within 7 days prior to treatment and sequential posttreatment viral cultures of urine, blood, throat and/or semen. As judged by conversion to culture negativity, or a greater than 100-fold decrease

in in vitro CMV titer, at least 83% of patients had a virologic response with a median response time of 7 to 15 days.

Antiviral activity of CYMEVENE-IV was demonstrated in two randomized studies for the prevention of CMV disease in transplant recipients (see **Table 1**).

**Table 1 Patients With Positive CMV Cultures**

Time	Heart Allograft* (n = 147)		Bone Marrow Allograft (n = 72)	
	CYMEVENE-IV†	Placebo	CYMEVENE-IV‡	Placebo
Pretreatment	1/67 (2%)	5/64 (8%)	37/37 (100%)	35/35 (100%)
Week 2	2/75 (3%)	11/67 (16%)	2/31 (6%)	19/28 (68%)
Week 4	3/66 (5%)	28/66 (43%)	0/24 (0%)	16/20 (80%)

\* CMV seropositive or receiving graft from seropositive donor

† 5 mg/kg bid for 14 days followed by 6 mg/kg qd for 5 days/week for 14 days

‡ 5 mg/kg bid for 7 days followed by 5 mg/kg qd until day 100 posttransplant

### Ganciclovir Capsules

In trials comparing CYMEVENE-IV with Ganciclovir capsules for the maintenance treatment of CMV retinitis in patients with AIDS, serial urine cultures and other available cultures (semen, biopsy specimens, blood and others) showed that a small proportion of patients remained culture-positive during maintenance therapy with no statistically significant differences in CMV isolation rates between treatment groups.

### Viral Resistance

The current working definition of CMV resistance to ganciclovir in in vitro assays is IC<sub>50</sub> >3.0 µg/mL (12.0 µM). CMV resistance to ganciclovir has been observed in individuals with AIDS and CMV retinitis who have never received ganciclovir therapy. Viral resistance has also been observed in patients receiving prolonged treatment for CMV retinitis with CYMEVENE-IV. In a controlled study of oral ganciclovir for prevention of AIDS-associated CMV disease, 364 individuals had one or more cultures performed after at least 90 days of ganciclovir treatment. Of these, 113 had at least one positive culture. The last available isolate from each subject was tested for reduced sensitivity, and 2 of 40 were found to be resistant to ganciclovir. These resistant isolates were associated with subsequent treatment failure for retinitis.

The possibility of viral resistance should be considered in patients who show poor clinical response or experience persistent viral excretion during therapy. The principal mechanism of resistance to ganciclovir in CMV is the decreased ability to form the active triphosphate moiety; resistant viruses have been described that contain mutations in the UL97 gene of CMV that controls phosphorylation of ganciclovir. Mutations in the viral DNA polymerase have also been reported to confer viral resistance to ganciclovir.

## CLINICAL PHARMACOLOGY

### Pharmacokinetics

**BECAUSE THE MAJOR ELIMINATION PATHWAY FOR GANCICLOVIR IS RENAL, DOSAGE REDUCTIONS ACCORDING TO CREATININE CLEARANCE ARE REQUIRED FOR CYMEVENE-IV. FOR DOSING INSTRUCTIONS IN PATIENTS WITH RENAL IMPAIRMENT, REFER TO DOSAGE AND ADMINISTRATION.**

### Absorption

At the end of a 1-hour intravenous infusion of 5 mg/kg ganciclovir, total AUC ranged between  $22.1 \pm 3.2$  (n=16) and  $26.8 \pm 6.1$   $\mu\text{g}\cdot\text{hr}/\text{mL}$  (n=16) and  $C_{\text{max}}$  ranged between  $8.27 \pm 1.02$  (n=16) and  $9.0 \pm 1.4$   $\mu\text{g}/\text{mL}$  (n=16).

### Distribution

The steady-state volume of distribution of ganciclovir after intravenous administration was  $0.74 \pm 0.15$  L/kg (n=98). Cerebrospinal fluid concentrations obtained 0.25 to 5.67 hours postdose in 3 patients who received 2.5 mg/kg ganciclovir intravenously q8h or q12h ranged from 0.31 to 0.68  $\mu\text{g}/\text{mL}$  representing 24% to 70% of the respective plasma concentrations. Binding to plasma proteins was 1% to 2% over ganciclovir concentrations of 0.5 and 51  $\mu\text{g}/\text{mL}$ .

### Elimination

When administered intravenously, ganciclovir exhibits linear pharmacokinetics over the range of 1.6 to 5.0 mg/kg and when administered orally, it exhibits linear kinetics up to a total daily dose of 4 g/day. Renal excretion of unchanged drug by glomerular filtration and active tubular secretion is the major route of elimination of ganciclovir. In patients with normal renal function,  $91.3 \pm 5.0\%$  (n=4) of intravenously administered ganciclovir was recovered unmetabolized in the urine. Systemic clearance of intravenously administered ganciclovir was  $3.52 \pm 0.80$  mL/min/kg (n=98) while renal clearance was  $3.20 \pm 0.80$  mL/min/kg (n=47), accounting for  $91 \pm 11\%$  of the systemic clearance (n=47). Half-life was  $3.5 \pm 0.9$  hours (n=98) following IV administration and  $4.8 \pm 0.9$  hours (n=39) following oral administration.

### Special Populations

#### Renal Impairment

The pharmacokinetics following intravenous administration of CYMEVENE-IV solution were evaluated in 10 immunocompromised patients with renal impairment who received doses ranging from 1.25 to 5.0 mg/kg.

**Table 2 Pharmacokinetics of Patients with Renal Impairment**

Estimated Creatinine Clearance (mL/min)	n	Dose	Clearance (mL/min) Mean ± SD	Half-life (hours) Mean ± SD
50-79	4	3.2-5 mg/kg	128 ± 63	4.6 ± 1.4
25-49	3	3-5 mg/kg	57 ± 8	4.4 ± 0.4
<25	3	1.25-5 mg/kg	30 ± 13	10.7 ± 5.7

Based on these observations, it is necessary to modify the dosage of ganciclovir in patients with renal impairment (see **DOSAGE AND ADMINISTRATION**).

Hemodialysis reduces plasma concentrations of ganciclovir by about 50% after intravenous administration.

#### Race/Ethnicity and Gender

The effects of race/ethnicity and gender were studied in subjects receiving a dose regimen of 1000 mg every 8 hours. Although the numbers of blacks (16%) and Hispanics (20%) were small, there appeared to be a trend towards a lower steady-state  $C_{max}$  and  $AUC_{0-8}$  in these subpopulations as compared to Caucasians. No definitive conclusions regarding gender differences could be made because of the small number of females (12%); however, no differences between males and females were observed.

#### Pediatrics

Ganciclovir pharmacokinetics were studied in 27 neonates, aged 2 to 49 days. At an intravenous dose of 4 mg/kg (n=14) or 6 mg/kg (n=13), the pharmacokinetic parameters were, respectively,  $C_{max}$  of  $5.5 \pm 1.6$  and  $7.0 \pm 1.6$  µg/mL, systemic clearance of  $3.14 \pm 1.75$  and  $3.56 \pm 1.27$  mL/min/kg, and  $t_{1/2}$  of 2.4 hours (harmonic mean) for both.

Ganciclovir pharmacokinetics were also studied in 10 pediatric patients, aged 9 months to 12 years. The pharmacokinetic characteristics of ganciclovir were the same after single and multiple (q12h) intravenous doses (5 mg/kg). The steady-state volume of distribution was  $0.64 \pm 0.22$  L/kg,  $C_{max}$  was  $7.9 \pm 3.9$  µg/mL, systemic clearance was  $4.7 \pm 2.2$  mL/min/kg, and  $t_{1/2}$  was  $2.4 \pm 0.7$  hours. The pharmacokinetics of intravenous ganciclovir in pediatric patients are similar to those observed in adults.

#### Elderly

No studies have been conducted in adults older than 65 years of age.

### INDICATIONS AND USAGE

CYMEVENE-IV is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). CYMEVENE-IV is also indicated for the prevention of CMV disease in transplant recipients at risk for CMV disease (see **CLINICAL TRIALS**).

SAFETY AND EFFICACY OF **CYMEVENE-IV** HAVE NOT BEEN ESTABLISHED FOR CONGENITAL OR NEONATAL CMV DISEASE; NOR FOR THE TREATMENT OF ESTABLISHED CMV DISEASE OTHER THAN RETINITIS; NOR FOR USE IN NON-IMMUNOCOMPROMISED INDIVIDUALS.

**CLINICAL TRIALS**

**1. Treatment of CMV Retinitis**

The diagnosis of CMV retinitis should be made by indirect ophthalmoscopy. Other conditions in the differential diagnosis of CMV retinitis include candidiasis, toxoplasmosis, histoplasmosis, retinal scars and cotton wool spots, any of which may produce a retinal appearance similar to CMV. For this reason it is essential that the diagnosis of CMV be established by an ophthalmologist familiar with the retinal presentation of these conditions. The diagnosis of CMV retinitis may be supported by culture of CMV from urine, blood, throat or other sites, but a negative CMV culture does not rule out CMV retinitis.

Studies with CYMEVENE-IV

In a retrospective, non-randomized, single-center analysis of 41 patients with AIDS and CMV retinitis diagnosed by ophthalmologic examination between August 1983 and April 1988, treatment with CYMEVENE-IV solution resulted in a significant delay in mean (median) time to first retinitis progression compared to untreated controls [105 (71) days from diagnosis vs 35 (29) days from diagnosis]. Patients in this series received induction treatment of CYMEVENE-IV 5 mg/kg bid for 14 to 21 days followed by maintenance treatment with either 5 mg/kg once daily, 7 days per week or 6 mg/kg once daily, 5 days per week (see **DOSAGE AND ADMINISTRATION**).

In a controlled, randomized study conducted between February 1989 and December 1990,<sup>1</sup> immediate treatment with CYMEVENE-IV was compared to delayed treatment in 42 patients with AIDS and peripheral CMV retinitis; 35 of 42 patients (13 in the immediate-treatment group and 22 in the delayed-treatment group) were included in the analysis of time to retinitis progression. Based on masked assessment of fundus photographs, the mean [95% CI] and median [95% CI] times to progression of retinitis were 66 days [39, 94] and 50 days [40, 84], respectively, in the immediate-treatment group compared to 19 days [11, 27] and 13.5 days [8, 18], respectively, in the delayed-treatment group.

Studies Comparing Ganciclovir Capsules to CYMEVENE-IV

**Table 3 Population Characteristics in Studies ICM 1653, ICM 1774 and AVI 034**

		ICM 1653 (n=121)	ICM 1774 (n=225)	AVI 034 (n=159)
Median age (years)		38	37	39
Range		24-62	22-56	23-62
Sex	Males	116 (96%)	222 (99%)	148 (93%)
	Females	5 (4%)	3 (1%)	10 (6%)
Ethnicity	Asian	3 (3%)	5 (2%)	7 (4%)
	Black	11 (9%)	9 (4%)	3 (2%)

	Caucasian	98 (81%)	186 (83%)	140 (88%)
	Other	9 (7%)	25 (11%)	8 (5%)
Median CD <sub>4</sub> Count		9.5	7.0	10.0
Range		0-141	0-80	0-320
Mean (SD)				
Observation Time (days)		107.9 (43.0)	97.6 (42.5)	80.9 (47.0)


*ICM 1653:* In this randomized, open-label, parallel group trial, conducted between March 1991 and November 1992, patients with AIDS and newly diagnosed CMV retinitis received a 3-week induction course of CYMEVENE-IV solution, 5 mg/kg bid for 14 days followed by 5 mg/kg once daily for 1 additional week.<sup>2</sup> Following the 21-day intravenous induction course, patients with stable CMV retinitis were randomized to receive 20 weeks of maintenance treatment with either CYMEVENE-IV solution, 5 mg/kg once daily, or ganciclovir capsules, 500 mg 6 times daily (3000 mg/day). The study showed that the mean [95% CI] and median [95% CI] times to progression of CMV retinitis, as assessed by masked reading of fundus photographs, were 57 days [44, 70] and 29 days [28, 43], respectively, for patients on oral therapy compared to 62 days [50, 73] and 49 days [29, 61], respectively, for patients on intravenous therapy. The difference [95% CI] in the mean time to progression between the oral and intravenous therapies (oral - IV) was -5 days [-22, 12]. See **Figure 1** for comparison of the proportion of patients remaining free of progression over time.

*ICM 1774:* In this three-arm, randomized, open-label, parallel group trial, conducted between June 1991 and August 1993, patients with AIDS and stable CMV retinitis following from 4 weeks to 4 months of treatment with CYMEVENE-IV solution were randomized to receive maintenance treatment with CYMEVENE-IV solution, 5 mg/kg once daily, ganciclovir capsules, 500 mg 6 times daily, or ganciclovir capsules, 1000 mg tid for 20 weeks. The study showed that the mean [95% CI] and median [95% CI] times to progression of CMV retinitis, as assessed by masked reading of fundus photographs, were 54 days [48, 60] and 42 days [31, 54], respectively, for patients on oral therapy compared to 66 days [56, 76] and 54 days [41, 69], respectively, for patients on intravenous therapy. The difference [95% CI] in the mean time to progression between the oral and intravenous therapies (oral - IV) was -12 days [-24, 0]. See **Figure 2** for comparison of the proportion of patients remaining free of progression over time.


*AVI 034:* In this randomized, open-label, parallel group trial, conducted between June 1991 and February 1993, patients with AIDS and newly diagnosed (81%) or previously treated (19%) CMV retinitis who had tolerated 10 to 21 days of induction treatment with CYMEVENE-IV, 5 mg/kg twice daily, were randomized to receive 20 weeks of maintenance treatment with either ganciclovir capsules, 500 mg 6 times daily or CYMEVENE-IV solution, 5 mg/kg/day.<sup>3</sup> The mean [95% CI] and median [95% CI] times to progression of CMV retinitis, as assessed by masked reading of fundus photographs, were 51 days [44, 57] and 41 days [31, 45], respectively, for patients on oral therapy compared to 62 days [52, 72] and 60 days [42, 83], respectively, for patients on intravenous therapy. The difference [95% CI] in the mean time to progression between the oral and intravenous therapies (oral - IV) was -11 days [-24, 1]. See **Figure 3** for comparison of the proportion of patients remaining free of progression over time.

Comparison of other CMV retinitis outcomes between oral and IV formulations (development of bilateral retinitis, progression into Zone 1, and deterioration of visual acuity), while not definitive, showed no marked differences between treatment groups in these studies. Because of low event rates among these endpoints, these studies are underpowered to rule out significant differences in these endpoints.


**Figure 1 ICM 1653**



**Figure 2 ICM 1774**



**Figure 3 AVI 034**



## 2. Prevention of CMV Disease in Transplant Recipients

CYMEVENE-IV was evaluated in three randomized, controlled trials of prevention of CMV disease in organ transplant recipients.

*ICM 1496:* In a randomized, double-blind, placebo-controlled study of 149 heart transplant recipients<sup>4</sup> at risk for CMV infection (CMV seropositive or a seronegative recipient of an organ from a CMV seropositive donor), there was a statistically significant reduction in the overall incidence of CMV disease in patients treated with CYMEVENE-IV. Immediately posttransplant, patients received CYMEVENE-IV solution 5 mg/kg bid for 14 days followed by 6 mg/kg qd for 5 days/week for an additional 14 days. Twelve of the 76 (16%) patients treated with CYMEVENE-IV vs 31 of the 73 (43%) placebo-treated patients developed CMV disease during the 120-day posttransplant observation period. No significant differences in hematologic toxicities were seen between the two treatment groups (refer to **Table 6** in **ADVERSE EVENTS**).

*ICM 1689:* In a randomized, double-blind, placebo-controlled study of 72 bone marrow transplant recipients<sup>5</sup> with asymptomatic CMV infection (CMV positive culture of urine, throat or blood) there was a statistically significant reduction in the incidence of CMV disease in patients treated with CYMEVENE-IV following successful hematopoietic engraftment. Patients with virologic evidence of CMV infection received CYMEVENE-IV solution 5 mg/kg bid for 7 days followed by 5 mg/kg qd through day 100 posttransplant. One of the 37 (3%) patients treated with CYMEVENE-IV vs 15 of the 35 (43%) placebo-treated patients developed CMV disease during the study. At 6 months posttransplant, there continued to be a statistically significant reduction in the incidence of CMV disease in patients treated with CYMEVENE-IV. Six of 37 (16%) patients treated with CYMEVENE-IV vs 15 of the 35 (43%) placebo-treated patients developed disease through 6 months posttransplant. The overall rate of survival was statistically significantly higher in the group treated with CYMEVENE-IV, both at day 100 and day 180 posttransplant. Although the differences in hematologic toxicities were not statistically significant, the incidence of neutropenia was higher in the group treated with CYMEVENE-IV (refer to **Table 6** in **ADVERSE EVENTS**).

*ICM 1570*: A second, randomized, unblinded study evaluated 40 allogeneic bone marrow transplant recipients at risk for CMV disease.<sup>6</sup> Patients underwent bronchoscopy and bronchoalveolar lavage (BAL) on day 35 posttransplant. Patients with histologic, immunologic or virologic evidence of CMV infection in the lung were then randomized to observation or treatment with CYMEVENE-IV solution (5 mg/kg bid for 14 days followed by 5 mg/kg qd 5 days/week until day 120). Four of 20 (20%) patients treated with CYMEVENE-IV and 14 of 20 (70%) control patients developed interstitial pneumonia. The incidence of CMV disease was significantly lower in the group treated with CYMEVENE-IV, consistent with the results observed in ICM 1689.

## CONTRAINDICATIONS

CYMEVENE-IV is contraindicated in patients with hypersensitivity to ganciclovir or acyclovir.

## WARNINGS

### Hematologic

**CYMEVENE-IV should not be administered if the absolute neutrophil count is less than 500 cells/ $\mu$ L or the platelet count is less than 25,000 cells/ $\mu$ L.** Granulocytopenia (neutropenia), anemia and thrombocytopenia have been observed in patients treated with CYMEVENE-IV. The frequency and severity of these events vary widely in different patient populations (see **ADVERSE EVENTS**).

CYMEVENE-IV should, therefore, be used with caution in patients with pre-existing cytopenias or with a history of cytopenic reactions to other drugs, chemicals or irradiation. Granulocytopenia usually occurs during the first or second week of treatment but may occur at any time during treatment. Cell counts usually begin to recover within 3 to 7 days of discontinuing drug. Colony-stimulating factors have been shown to increase neutrophil and white blood cell counts in patients receiving CYMEVENE-IV solution for treatment of CMV retinitis.

### Impairment of Fertility

Animal data indicate that administration of ganciclovir causes inhibition of spermatogenesis and subsequent infertility. These effects were reversible at lower doses and irreversible at higher doses (see **PRECAUTIONS: Carcinogenesis, Mutagenesis† and Impairment of Fertility†**). Although data in humans have not been obtained regarding this effect, it is considered probable that ganciclovir at the recommended doses causes temporary or permanent inhibition of spermatogenesis. Animal data also indicate that suppression of fertility in females may occur.

### Teratogenesis

Because of the mutagenic and teratogenic potential of ganciclovir, women of childbearing potential should be advised to use effective contraception during treatment. Similarly, men should be advised to practice barrier contraception during and for at least 90 days

following treatment with CYMEVENE-IV (see **PRECAUTIONS: Pregnancy†: Category C**).

## **PRECAUTIONS**

### **General**

In clinical studies with CYMEVENE-IV, the maximum single dose administered was 6 mg/kg by intravenous infusion over 1 hour. Larger doses have resulted in increased toxicity. It is likely that more rapid infusions would also result in increased toxicity (see **OVERDOSAGE**). Administration of CYMEVENE-IV solution should be accompanied by adequate hydration.

Initially reconstituted solutions of CYMEVENE-IV have a high pH (pH 11). Despite further dilution in intravenous fluids, phlebitis and/or pain may occur at the site of intravenous infusion. Care must be taken to infuse solutions containing CYMEVENE-IV only into veins with adequate blood flow to permit rapid dilution and distribution (see **DOSAGE AND ADMINISTRATION**).

Since ganciclovir is excreted by the kidneys, normal clearance depends on adequate renal function. IF RENAL FUNCTION IS IMPAIRED, DOSAGE ADJUSTMENTS ARE REQUIRED FOR CYMEVENE-IV. Such adjustments should be based on measured or estimated creatinine clearance values (see **DOSAGE AND ADMINISTRATION**).

### **Information for Patients**

All patients should be informed that the major toxicities of ganciclovir are granulocytopenia (neutropenia), anemia and thrombocytopenia and that dose modifications may be required, including discontinuation. The importance of close monitoring of blood counts while on therapy should be emphasized. Patients should be informed that ganciclovir has been associated with elevations in serum creatinine.

Patients should be advised that ganciclovir has caused decreased sperm production in animals and may cause infertility in humans. Women of childbearing potential should be advised that ganciclovir causes birth defects in animals and should not be used during pregnancy. Women of childbearing potential should be advised to use effective contraception during treatment with CYMEVENE-IV. Similarly, men should be advised to practice barrier contraception during and for at least 90 days following treatment with CYMEVENE-IV.

Patients should be advised that ganciclovir causes tumors in animals. Although there is no information from human studies, ganciclovir should be considered a potential carcinogen.

### **All HIV+ Patients**

These patients may be receiving zidovudine. Patients should be counseled that treatment with both ganciclovir and zidovudine simultaneously may not be tolerated by some patients and may result in severe granulocytopenia (neutropenia). Patients with AIDS may be receiving didanosine. Patients should be counseled that concomitant treatment with

both ganciclovir and didanosine can cause didanosine serum concentrations to be significantly increased.

#### HIV+ Patients With CMV Retinitis

Ganciclovir is not a cure for CMV retinitis, and immunocompromised patients may continue to experience progression of retinitis during or following treatment. Patients should be advised to have ophthalmologic follow-up examinations at a minimum of every 4 to 6 weeks while being treated with CYMEVENE-IV. Some patients will require more frequent follow-up.

#### Transplant Recipients

Transplant recipients should be counseled regarding the high frequency of impaired renal function in transplant recipients who received CYMEVENE-IV solution in controlled clinical trials, particularly in patients receiving concomitant administration of nephrotoxic agents such as cyclosporine and amphotericin B. Although the specific mechanism of this toxicity, which in most cases was reversible, has not been determined, the higher rate of renal impairment in patients receiving CYMEVENE-IV solution compared with those who received placebo in the same trials may indicate that CYMEVENE-IV played a significant role.

#### Laboratory Testing

Due to the frequency of neutropenia, anemia and thrombocytopenia in patients receiving CYMEVENE-IV (see **ADVERSE EVENTS**), it is recommended that complete blood counts and platelet counts be performed frequently, especially in patients in whom ganciclovir or other nucleoside analogues have previously resulted in leukopenia, or in whom neutrophil counts are less than 1000 cells/ $\mu$ L at the beginning of treatment. Increased serum creatinine levels have been observed in trials evaluating both CYMEVENE-IV. Patients should have serum creatinine or creatinine clearance values monitored carefully to allow for dosage adjustments in renally impaired patients (see **DOSAGE AND ADMINISTRATION**).

#### Drug Interactions

##### Didanosine

When the standard intravenous ganciclovir induction dose (5 mg/kg infused over 1 hour every 12 hours) was coadministered with didanosine at a dose of 200 mg orally every 12 hours, the steady-state didanosine  $AUC_{0-12}$  increased  $70 \pm 40\%$  (range: 3% to 121%, n=11) and  $C_{max}$  increased  $49 \pm 48\%$  (range: -28% to 125%). In a separate study, when the standard intravenous ganciclovir maintenance dose (5 mg/kg infused over 1 hour every 24 hours) was coadministered with didanosine at a dose of 200 mg orally every 12 hours, didanosine  $AUC_{0-12}$  increased  $50 \pm 26\%$  (range: 22% to 110%, n=11) and  $C_{max}$  increased  $36 \pm 36\%$  (range: -27% to 94%) over the first didanosine dosing interval. Didanosine plasma concentrations ( $AUC_{12-24}$ ) were unchanged during the dosing intervals when ganciclovir was not coadministered. Ganciclovir pharmacokinetics were not affected by

didanosine. In neither study were there significant changes in the renal clearance of either drug.

#### Zidovudine

At an oral dose of 1000 mg of ganciclovir every 8 hours, mean steady-state ganciclovir AUC<sub>0-8</sub> decreased  $17 \pm 25\%$  (range: -52% to 23%) in the presence of zidovudine, 100 mg every 4 hours (n=12). Steady-state zidovudine AUC<sub>0-4</sub> increased  $19 \pm 27\%$  (range: -11% to 74%) in the presence of ganciclovir. No drug-drug interaction studies have been conducted with IV ganciclovir and zidovudine.

Since both zidovudine and ganciclovir have the potential to cause neutropenia and anemia, some patients may not tolerate concomitant therapy with these drugs at full dosage.

#### Probenecid

At an oral dose of 1000 mg of ganciclovir every 8 hours (n=10), ganciclovir AUC<sub>0-8</sub> increased  $53 \pm 91\%$  (range: -14% to 299%) in the presence of probenecid, 500 mg every 6 hours. Renal clearance of ganciclovir decreased  $22 \pm 20\%$  (range: -54% to -4%), which is consistent with an interaction involving competition for renal tubular secretion. No drug-drug interaction studies have been conducted with IV ganciclovir and probenecid.

#### Imipenem-cilastatin

Generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. These drugs should not be used concomitantly unless the potential benefits outweigh the risks.

#### Other Medications

It is possible that drugs that inhibit replication of rapidly dividing cell populations such as bone marrow, spermatogonia and germinal layers of skin and gastrointestinal mucosa may have additive toxicity when administered concomitantly with ganciclovir. Therefore, drugs such as dapsone, pentamidine, flucytosine, vincristine, vinblastine, adriamycin, amphotericin B, trimethoprim/sulfamethoxazole combinations or other nucleoside analogues, should be considered for concomitant use with ganciclovir only if the potential benefits are judged to outweigh the risks.

No formal drug interaction studies of CYMEVENE-IV and drugs commonly used in transplant recipients have been conducted. Increases in serum creatinine were observed in patients treated with CYMEVENE-IV plus either cyclosporine or amphotericin B, drugs with known potential for nephrotoxicity (see **ADVERSE EVENTS**). In a retrospective analysis of 93 liver allograft recipients receiving ganciclovir (5 mg/kg infused over 1 hour every 12 hours) and oral cyclosporine (at therapeutic doses), there was no evidence of an effect on cyclosporine whole blood concentrations.

### **Carcinogenesis, Mutagenesis<sup>†</sup>**

Ganciclovir was carcinogenic in the mouse at oral doses of 20 and 1000 mg/kg/day (approximately 0.1x and 1.4x, respectively, the mean drug exposure in humans following the recommended intravenous dose of 5 mg/kg, based on area under the plasma concentration curve [AUC] comparisons). At the dose of 1000 mg/kg/day there was a significant increase in the incidence of tumors of the preputial gland in males, forestomach (nonglandular mucosa) in males and females, and reproductive tissues (ovaries, uterus, mammary gland, clitoral gland and vagina) and liver in females. At the dose of 20 mg/kg/day, a slightly increased incidence of tumors was noted in the preputial and harderian glands in males, forestomach in males and females, and liver in females. No carcinogenic effect was observed in mice administered ganciclovir at 1 mg/kg/day (estimated as 0.01x the human dose based on AUC comparison). Except for histiocytic sarcoma of the liver, ganciclovir-induced tumors were generally of epithelial or vascular origin. Although the preputial and clitoral glands, forestomach and harderian glands of mice do not have human counterparts, ganciclovir should be considered a potential carcinogen in humans.

Ganciclovir increased mutations in mouse lymphoma cells and DNA damage in human lymphocytes in vitro at concentrations between 50 to 500 and 250 to 2000 µg/mL, respectively. In the mouse micronucleus assay, ganciclovir was clastogenic at doses of 150 and 500 mg/kg (IV) (2.8 to 10x human exposure based on AUC) but not 50 mg/kg (exposure approximately comparable to the human based on AUC). Ganciclovir was not mutagenic in the Ames Salmonella assay at concentrations of 500 to 5000 µg/mL.

### **Impairment of Fertility<sup>†</sup>**

Ganciclovir caused decreased mating behavior, decreased fertility, and an increased incidence of embryoletality in female mice following intravenous doses of 90 mg/kg/day (approximately 1.7x the mean drug exposure in humans following the dose of 5 mg/kg, based on AUC comparisons). Ganciclovir caused decreased fertility in male mice and hypospermatogenesis in mice and dogs following daily oral or intravenous administration of doses ranging from 0.2 to 10 mg/kg. Systemic drug exposure (AUC) at the lowest dose showing toxicity in each species ranged from 0.03 to 0.1x the AUC of the recommended human intravenous dose.

### **Pregnancy<sup>†</sup>**

#### Category C

Ganciclovir has been shown to be embryotoxic in rabbits and mice following intravenous administration and teratogenic in rabbits. Fetal resorptions were present in at least 85% of rabbits and mice administered 60 mg/kg/day and 108 mg/kg/day (2x the human exposure based on AUC comparisons), respectively. Effects observed in rabbits included: fetal growth retardation, embryoletality, teratogenicity and/or maternal toxicity. Teratogenic changes included cleft palate, anophthalmia/microphthalmia, aplastic organs (kidney and pancreas), hydrocephaly and brachygnathia. In mice, effects observed were maternal/fetal toxicity and embryoletality.

Daily intravenous doses of 90 mg/kg administered to female mice prior to mating, during gestation, and during lactation caused hypoplasia of the testes and seminal vesicles in the month-old male offspring, as well as pathologic changes in the nonglandular region of the stomach (see **Carcinogenesis, Mutagenesis†**). The drug exposure in mice as estimated by the AUC was approximately 1.7x the human AUC.

Ganciclovir may be teratogenic or embryotoxic at dose levels recommended for human use. There are no adequate and well-controlled studies in pregnant women. CYMEVENE-IV should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.

†**Footnote:** All dose comparisons presented in the **Carcinogenesis, Mutagenesis†**, **Impairment of Fertility†**, and **Pregnancy†** subsections are based on the human AUC following administration of a single 5 mg/kg intravenous infusion of CYMEVENE-IV as used during the maintenance phase of treatment. Compared with the single 5 mg/kg intravenous infusion, human exposure is doubled during the intravenous induction phase (5 mg/kg bid). The cross-species dose comparisons should be divided by 2 for intravenous induction treatment with CYMEVENE-IV.

### **Nursing Mothers**

It is not known whether ganciclovir is excreted in human milk. However, many drugs are excreted in human milk and, because carcinogenic and teratogenic effects occurred in animals treated with ganciclovir, the possibility of serious adverse reactions from ganciclovir in nursing infants is considered likely (see **Pregnancy†: Category C**). Mothers should be instructed to discontinue nursing if they are receiving CYMEVENE-IV. The minimum interval before nursing can safely be resumed after the last dose of CYMEVENE-IV is unknown.

### **Pediatric Use**

**SAFETY AND EFFICACY OF CYMEVENE-IV IN PEDIATRIC PATIENTS HAVE NOT BEEN ESTABLISHED. THE USE OF CYMEVENE-IV IN THE PEDIATRIC POPULATION WARRANTS EXTREME CAUTION DUE TO THE PROBABILITY OF LONG-TERM CARCINOGENICITY AND REPRODUCTIVE TOXICITY. ADMINISTRATION TO PEDIATRIC PATIENTS SHOULD BE UNDERTAKEN ONLY AFTER CAREFUL EVALUATION AND ONLY IF THE POTENTIAL BENEFITS OF TREATMENT OUTWEIGH THE RISKS.**

The spectrum of adverse events reported in 120 immunocompromised pediatric clinical trial participants with serious CMV infections receiving CYMEVENE-IV solution were similar to those reported in adults. Granulocytopenia (17%) and thrombocytopenia (10%) were the most common adverse events reported.

Sixteen pediatric patients (8 months to 15 years of age) with life- or sight-threatening CMV infections were evaluated in an open-label, CYMEVENE-IV solution, pharmacokinetics study. Adverse events reported for more than one pediatric patient were as follows: hypokalemia (4/16, 25%), abnormal kidney function (3/16, 19%), sepsis (3/16, 19%), thrombocytopenia (3/16, 19%), leukopenia (2/16, 13%), coagulation disorder (2/16, 13%),

hypertension (2/16, 13%), pneumonia (2/16, 13%) and immune system disorder (2/16, 13%).

There has been very limited clinical experience using CYMEVENE-IV for the treatment of CMV retinitis in patients under the age of 12 years. Two pediatric patients (ages 9 and 5 years) showed improvement or stabilization of retinitis for 23 and 9 months, respectively. These pediatric patients received induction treatment with 2.5 mg/kg tid followed by maintenance therapy with 6 to 6.5 mg/kg once per day, 5 to 7 days per week. When retinitis progressed during once-daily maintenance therapy, both pediatric patients were treated with the 5 mg/kg bid regimen. Two other pediatric patients (ages 2.5 and 4 years) who received similar induction regimens showed only partial or no response to treatment. Another pediatric patient, a 6-year-old with T-cell dysfunction, showed stabilization of retinitis for 3 months while receiving continuous infusions of CYMEVENE-IV at doses of 2 to 5 mg/kg/24 hours. Continuous infusion treatment was discontinued due to granulocytopenia.

Eleven of the 72 patients in the placebo-controlled trial in bone marrow transplant recipients were pediatric patients, ranging in age from 3 to 10 years (5 treated with CYMEVENE-IV and 6 with placebo). Five of the pediatric patients treated with CYMEVENE-IV received 5 mg/kg intravenously bid for up to 7 days; 4 patients went on to receive 5 mg/kg qd up to day 100 posttransplant. Results were similar to those observed in adult transplant recipients treated with CYMEVENE-IV. Two of the 6 placebo-treated pediatric patients developed CMV pneumonia vs none of the 5 patients treated with CYMEVENE-IV. The spectrum of adverse events in the pediatric group was similar to that observed in the adult patients.

### **Geriatric Use**

The pharmacokinetic profiles of CYMEVENE-IV in elderly patients have not been established. Since elderly individuals frequently have a reduced glomerular filtration rate, particular attention should be paid to assessing renal function before and during administration of CYMEVENE-IV (see **DOSAGE AND ADMINISTRATION**).

Clinical studies of CYMEVENE-IV did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. CYMEVENE-IV is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. In addition, renal function should be monitored and dosage adjustments should be made accordingly (see **Use in Patients With Renal Impairment** and **DOSAGE AND ADMINISTRATION**).

### **Use in Patients With Renal Impairment**

CYMEVENE-IV should be used with caution in patients with impaired renal function because the half-life and plasma/serum concentrations of ganciclovir will be increased due

to reduced renal clearance (see **DOSAGE AND ADMINISTRATION** and **ADVERSE EVENTS**).

Hemodialysis has been shown to reduce plasma levels of ganciclovir by approximately 50%.

### ADVERSE EVENTS

Adverse events that occurred during clinical trials of CYMEVENE-IV solution are summarized below, according to the participating study subject population.

### Subjects With AIDS

Three controlled, randomized, phase 3 trials comparing CYMEVENE-IV and ganciclovir capsules for maintenance treatment of CMV retinitis have been completed. During these trials, CYMEVENE-IV or ganciclovir capsules were prematurely discontinued in 9% of subjects because of adverse events. Laboratory data and adverse events reported during the conduct of these controlled trials are summarized below.

#### Laboratory Data

**Table 4 Selected Laboratory Abnormalities in Trials for Treatment of CMV Retinitis**

Treatment	CMV Retinitis Treatment*	
	Ganciclovir Capsules† 3000 mg/day	CYMEVENE-IV‡ 5 mg/kg/day
Subjects, number	320	175
Neutropenia:		
<500 ANC/ $\mu$ L	18%	25%
500 – <749	17%	14%
750 – <1000	19%	26%
Anemia		
Hemoglobin:		
<6.5 g/dL	2%	5%
6.5 – <8.0	10%	16%
8.0 – <9.5	25%	26%
Maximum Serum Creatinine:		
$\geq$ 2.5 mg/dL	1%	2%
$\geq$ 1.5 – <2.5	12%	14%

\* Pooled data from Treatment Studies, ICM 1653, Study ICM 1774 and Study AVI 034

† Mean time on therapy = 91 days, including allowed reinduction treatment periods

‡ Mean time on therapy = 103 days, including allowed reinduction treatment periods

(See **CLINICAL TRIALS**.)

#### Adverse Events

The following table shows selected adverse events reported in 5% or more of the subjects in three controlled clinical trials during treatment with either CYMEVENE-IV

solution (5 mg/kg/day) or ganciclovir capsules (3000 mg/day), and in one controlled clinical trial with CYMEVENE capsules (3000 mg/day).

**Table 5 Selected Adverse Events Reported in  $\geq 5\%$  of Subjects in Three Randomized Phase 3 Studies Comparing Ganciclovir Capsules to CYMEVENE-IV Solution for Maintenance Treatment of CMV Retinitis**

Body System	Adverse Event	Maintenance Treatment Studies	
		Capsules (n=326)	IV (n=179)
Body as a Whole	Fever	38%	48%
	Infection	9%	13%
	Chills	7%	10%
	Sepsis	4%	15%
Digestive System	Diarrhea	41%	44%
	Anorexia	15%	14%
	Vomiting	13%	13%
Hemic and Lymphatic System	Leukopenia	29%	41%
	Anemia	19%	25%
	Thrombocytopenia	6%	6%
Nervous System	Neuropathy	8%	9%
Other	Sweating	11%	12%
	Pruritus	6%	5%
Catheter Related*	Total Catheter Events	6%	22%
	Catheter Infection	4%	9%
	Catheter Sepsis	1%	8%

\*Some of these events also appear under other body systems.

The following events were frequently observed in clinical trials but occurred with equal or greater frequency in placebo-treated subjects: abdominal pain, nausea, flatulence, pneumonia, paresthesia, rash.

#### Retinal Detachment

Retinal detachment has been observed in subjects with CMV retinitis both before and after initiation of therapy with ganciclovir. Its relationship to therapy with ganciclovir is unknown. Retinal detachment occurred in 11% of patients treated with CYMEVENE-IV solution and in 8% of patients treated with ganciclovir capsules. Patients with CMV retinitis should have frequent ophthalmologic evaluations to monitor the status of their retinitis and to detect any other retinal pathology.

### Transplant Recipients

There have been three controlled clinical trials of CYMEVENE-IV solution for the prevention of CMV disease in transplant recipients. Laboratory data and adverse events reported during these trials are summarized below.

#### Laboratory Data

The following table shows the frequency of granulocytopenia (neutropenia) and thrombocytopenia observed:

**Table 6                      Controlled Trials – Transplant Recipients**

	CYMEVENE-IV			
	Heart Allograft*		Bone Marrow Allograft†	
	CYMEVENE-IV (n=76)	Placebo (n=73)	CYMEVENE-IV (n=57)	Control (n=55)
Neutropenia				
Minimum ANC <500/ $\mu$ L	4%	3%	12%	6%
Minimum ANC 500-1000/ $\mu$ L	3%	8%	29%	17%
TOTAL ANC $\leq$ 1000/ $\mu$ L	7%	11%	41%	23%
Thrombocytopenia				
Platelet count <25,000/ $\mu$ L	3%	1%	32%	28%
Platelet count 25,000- 50,000/ $\mu$ L	5%	3%	25%	37%
TOTAL Platelet $\leq$ 50,000/ $\mu$ L	8%	4%	57%	65%

\* Study ICM 1496. Mean duration of treatment = 28 days

† Study ICM 1570 and ICM 1689. Mean duration of treatment = 45 days  
(See **CLINICAL TRIALS.**)

The following table shows the frequency of elevated serum creatinine values in these controlled clinical trials:

**Table 7                      Controlled Trials - Transplant Recipients**

	CYMEVENE-IV					
	Heart Allograft ICM1496		Bone Marrow Allograft ICM 1570		Bone Marrow Allograft ICM 1689	
Maximum Serum Creatinine Levels	CYMEVENE-IV (n=76)	Placebo (n=73)	CYMEVENE-IV (n=20)	Control (n=20)	CYMEVENE-IV (n=37)	Placebo (n=35)
Serum Creatinine ≥2.5 mg/dL	18%	4%	20%	0%	0%	0%
Serum Creatinine ≥1.5 <2.5 mg/dL	58%	69%	50%	35%	43%	44%

In these three trials, patients receiving CYMEVENE-IV solution had elevated serum creatinine levels when compared to those receiving placebo. Most patients in these studies also received cyclosporine. The mechanism of impairment of renal function is not known. However, careful monitoring of renal function during therapy with CYMEVENE-IV solution is essential, especially for those patients receiving concomitant agents that may cause nephrotoxicity.

**General**

Other adverse events that were thought to be “probably” or “possibly” related to CYMEVENE-IV solution or ganciclovir capsules in controlled clinical studies in either subjects with AIDS or transplant recipients are listed below. These events all occurred in at least 3 subjects.

*Body as a Whole:* abdomen enlarged, asthenia, chest pain, edema, headache, injection site inflammation, malaise, pain

*Digestive System:* abnormal liver function test, aphthous stomatitis, constipation, dyspepsia, eructation

*Hemic and Lymphatic System:* pancytopenia

*Respiratory System:* cough increased, dyspnea

*Nervous System:* abnormal dreams, anxiety, confusion, depression, dizziness, dry mouth, insomnia, seizures, somnolence, thinking abnormal, tremor

*Skin and Appendages:* alopecia, dry skin

*Special Senses:* abnormal vision, taste perversion, tinnitus, vitreous disorder

*Metabolic and Nutritional Disorders:* creatinine increased, SGOT increased, SGPT increased, weight loss

*Cardiovascular System:* hypertension, phlebitis, vasodilatation

*Urogenital System:* creatinine clearance decreased, kidney failure, kidney function abnormal, urinary frequency

*Musculoskeletal System:* arthralgia, leg cramps, myalgia, myasthenia

The following adverse events reported in patients receiving ganciclovir may be potentially fatal: gastrointestinal perforation, multiple organ failure, pancreatitis and sepsis.

### **Adverse Events Reported During Postmarketing Experience With CYMEVENE-IV and Ganciclovir Capsules**

The following events have been identified during postapproval use of the drug. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to either the seriousness, frequency of reporting, the apparent causal connection or a combination of these factors:

acidosis, allergic reaction, anaphylactic reaction, arthritis, bronchospasm, cardiac arrest, cardiac conduction abnormality, cataracts, cholelithiasis, cholestasis, congenital anomaly, dry eyes, dysesthesia, dysphasia, elevated triglyceride levels, encephalopathy, exfoliative dermatitis, extrapyramidal reaction, facial palsy, hallucinations, hemolytic anemia, hemolytic uremic syndrome, hepatic failure, hepatitis, hypercalcemia, hyponatremia, inappropriate serum ADH, infertility, intestinal ulceration, intracranial hypertension, irritability, loss of memory, loss of sense of smell, myelopathy, oculomotor nerve paralysis, peripheral ischemia, pulmonary fibrosis, renal tubular disorder, rhabdomyolysis, Stevens-Johnson syndrome, stroke, testicular hypotrophy, Torsades de Pointes, vasculitis, ventricular tachycardia

### **OVERDOSAGE**

Overdosage with CYMEVENE-IV has been reported in 17 patients (13 adults and 4 children under 2 years of age). Five patients experienced no adverse events following overdosage at the following doses: 7 doses of 11 mg/kg over a 3-day period (adult), single dose of 3500 mg (adult), single dose of 500 mg (72.5 mg/kg) followed by 48 hours of peritoneal dialysis (4-month-old), single dose of approximately 60 mg/kg followed by exchange transfusion (18-month-old), 2 doses of 500 mg instead of 31 mg (21-month-old).

Irreversible pancytopenia developed in 1 adult with AIDS and CMV colitis after receiving 3000 mg of CYMEVENE-IV solution on each of 2 consecutive days. He experienced worsening GI symptoms and acute renal failure that required short-term dialysis. Pancytopenia developed and persisted until his death from a malignancy several months later. Other adverse events reported following overdosage included: persistent bone

marrow suppression (1 adult with neutropenia and thrombocytopenia after a single dose of 6000 mg), reversible neutropenia or granulocytopenia (4 adults, overdoses ranging from 8 mg/kg daily for 4 days to a single dose of 25 mg/kg), hepatitis (1 adult receiving 10 mg/kg daily, and one 2 kg infant after a single 40 mg dose), renal toxicity (1 adult with transient worsening of hematuria after a single 500 mg dose, and 1 adult with elevated creatinine (5.2 mg/dL) after a single 5000 to 7000 mg dose), and seizure (1 adult with known seizure disorder after 3 days of 9 mg/kg). In addition, 1 adult received 0.4 mL (instead of 0.1 mL) CYMEVENE-IV solution by intravitreal injection, and experienced temporary loss of vision and central retinal artery occlusion secondary to increased intraocular pressure related to the injected fluid volume.

Since ganciclovir is dialyzable, dialysis may be useful in reducing serum concentrations. Adequate hydration should be maintained. The use of hematopoietic growth factors should be considered (see **DOSAGE AND ADMINISTRATION: Renal Impairment**).

### **DOSAGE AND ADMINISTRATION**

CAUTION - DO NOT ADMINISTER CYMEVENE-IV SOLUTION BY RAPID OR BOLUS INTRAVENOUS INJECTION. THE TOXICITY OF CYMEVENE-IV MAY BE INCREASED AS A RESULT OF EXCESSIVE PLASMA LEVELS.

CAUTION - INTRAMUSCULAR OR SUBCUTANEOUS INJECTION OF RECONSTITUTED CYMEVENE-IV SOLUTION MAY RESULT IN SEVERE TISSUE IRRITATION DUE TO HIGH pH (11).

#### **Dosage**

THE RECOMMENDED DOSE FOR CYMEVENE-IV SOLUTION SHOULD NOT BE EXCEEDED. THE RECOMMENDED INFUSION RATE FOR CYMEVENE-IV SOLUTION SHOULD NOT BE EXCEEDED.

#### **For Treatment of CMV Retinitis in Patients With Normal Renal Function**

##### Induction Treatment

The recommended initial dosage for patients with normal renal function is 5 mg/kg (given intravenously at a constant rate over 1 hour) every 12 hours for 14 to 21 days.

##### Maintenance Treatment

Following induction treatment, the recommended maintenance dosage of CYMEVENE-IV solution is 5 mg/kg given as a constant-rate intravenous infusion over 1 hour once daily, 7 days per week, or 6 mg/kg once daily, 5 days per week.

For patients who experience progression of CMV retinitis while receiving maintenance treatment with CYMEVENE-IV, reinduction treatment is recommended.

**For the Prevention of CMV Disease in Transplant Recipients With Normal Renal Function**

The recommended initial dosage of CYMEVENE-IV solution for patients with normal renal function is 5 mg/kg (given intravenously at a constant rate over 1 hour) every 12 hours for 7 to 14 days, followed by 5 mg/kg once daily, 7 days per week or 6 mg/kg once daily, 5 days per week.

The duration of treatment with CYMEVENE-IV solution in transplant recipients is dependent upon the duration and degree of immunosuppression. In controlled clinical trials in bone marrow allograft recipients, treatment with CYMEVENE-IV was continued until day 100 to 120 posttransplantation. CMV disease occurred in several patients who discontinued treatment with CYMEVENE-IV solution prematurely. In heart allograft recipients, the onset of newly diagnosed CMV disease occurred after treatment with CYMEVENE-IV was stopped at day 28 posttransplant, suggesting that continued dosing may be necessary to prevent late occurrence of CMV disease in this patient population (see **INDICATIONS AND USAGE** section for a more detailed discussion).

**Renal Impairment**

For patients with impairment of renal function, refer to **Table 8** for recommended doses of CYMEVENE-IV solution and adjust the dosing interval as indicated:

**Table 8 Dosing for Patients with Renal Impairment**

Creatinine Clearance* (mL/min)	CYMEVENE-IV Induction Dose (mg/kg)	Dosing Interval (hours)	CYMEVENE-IV Maintenance Dose (mg/kg)	Dosing Interval (hours)
≥70	5.0	12	5.0	24
50–69	2.5	12	2.5	24
25–49	2.5	24	1.25	24
10–24	1.25	24	0.625	24
<10	1.25	3 times per week, following hemodialysis	0.625	3 times per week, following hemodialysis

\* Creatinine clearance can be related to serum creatinine by the formulas given below.

$$\text{Creatinine clearance for males} = \frac{(140 - \text{age}[\text{yrs}]) (\text{body wt} [\text{kg}])}{(72) (\text{serum creatinine} [\text{mg/dL}])}$$

Creatinine clearance for females = 0.85 x male value

Dosing for patients undergoing hemodialysis should not exceed 1.25 mg/kg 3 times per week, following each hemodialysis session. CYMEVENE-IV should be given shortly after completion of the hemodialysis session, since hemodialysis has been shown to reduce plasma levels by approximately 50%.

### **Patient Monitoring**

Due to the frequency of granulocytopenia, anemia and thrombocytopenia in patients receiving ganciclovir (see **ADVERSE EVENTS**), it is recommended that complete blood counts and platelet counts be performed frequently, especially in patients in whom ganciclovir or other nucleoside analogues have previously resulted in cytopenia, or in whom neutrophil counts are less than 1000 cells/ $\mu$ L at the beginning of treatment. Patients should have serum creatinine or creatinine clearance values followed carefully to allow for dosage adjustments in renally impaired patients (see **DOSAGE AND ADMINISTRATION**).

### **Reduction of Dose**

Dosage reductions in renally impaired patients are required for CYMEVENE-IV (see **Renal Impairment**). Dosage reductions should also be considered for those with neutropenia, anemia and/or thrombocytopenia (see **ADVERSE EVENTS**). Ganciclovir should not be administered in patients with severe neutropenia (ANC less than 500/ $\mu$ L) or severe thrombocytopenia (platelets less than 25,000/ $\mu$ L).

### **Method of Preparation of CYMEVENE-IV Solution**

Each 10 mL clear glass vial contains ganciclovir sodium equivalent to 500 mg of ganciclovir and 46 mg of sodium. The contents of the vial should be prepared for administration in the following manner:

1. Reconstituted Solution:

- a. Reconstitute lyophilized CYMEVENE-IV by injecting 10 mL of Sterile Water for Injection, USP, into the vial.

**DO NOT USE BACTERIOSTATIC WATER FOR INJECTION CONTAINING PARABENS. IT IS INCOMPATIBLE WITH CYMEVENE-IV AND MAY CAUSE PRECIPITATION.**

- b. Shake the vial to dissolve the drug.
- c. Visually inspect the reconstituted solution for particulate matter and discoloration prior to proceeding with infusion solution. Discard the vial if particulate matter or discoloration is observed.
- d. Reconstituted solution in the vial is stable at room temperature for 12 hours. It should not be refrigerated.

2. Infusion Solution:

Based on patient weight, the appropriate volume of the reconstituted solution (ganciclovir concentration 50 mg/mL) should be removed from the vial and added to an acceptable infusion fluid (typically 100 mL) for delivery over the course of 1 hour. Infusion concentrations greater than 10 mg/mL are not recommended. The following infusion fluids have been determined to be chemically and physically compatible with CYMEVENE-IV solution: 0.9% Sodium Chloride, 5% Dextrose, Ringer's Injection and Lactated Ringer's Injection, USP.

CYMEVENE-IV, when reconstituted with sterile water for injection, further diluted with 0.9% sodium chloride injection, and stored refrigerated at 5°C in polyvinyl chloride (PVC) bags, remains physically and chemically stable for 14 days.

However, because CYMEVENE-IV is reconstituted with nonbacteriostatic sterile water, it is recommended that the infusion solution be used within 24 hours of dilution to reduce the risk of bacterial contamination. The infusion should be refrigerated. Freezing is not recommended.

### **Handling and Disposal**

Caution should be exercised in the handling and preparation of solutions of CYMEVENE-IV. Solutions of CYMEVENE-IV are alkaline (pH 11). Avoid direct contact of the skin or mucous membranes with CYMEVENE-IV solutions. If such contact occurs, wash thoroughly with soap and water; rinse eyes thoroughly with plain water.

Because ganciclovir shares some of the properties of antitumor agents (ie, carcinogenicity and mutagenicity), consideration should be given to handling and disposal according to guidelines issued for antineoplastic drugs. Several guidelines on this subject have been published.<sup>7-9</sup>

There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

### **HOW SUPPLIED**

CYMEVENE<sup>®</sup>-IV (ganciclovir sodium for injection) is supplied in 10 mL sterile vials, each containing ganciclovir sodium equivalent to 500 mg of ganciclovir, in cartons of 25 (NDC 0004-6940-03).

### **Storage**

Store vials at temperatures below 30°C

### **LICENSE HOLDER**

Roche Pharmaceuticals (Israel) Ltd., P.O.Box 6391, Hod Hasharon 4524079

### **LICENSE NUMBER**

CYMEVENE<sup>®</sup> 500 mg Vials 110.89.26101.00

**Cymevene<sup>®</sup>** is manufactured by F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.

Medicine: keep out of reach of children
---

**1181CYME0508**